{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:28:26Z","timestamp":1787243306076,"version":"build-2736575974"},"reference-count":52,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Diabetes Sci Technol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To evaluate the use of intermittently scanned continuous glucose monitoring (isCGM) in patients with liver cirrhosis (LC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Observational study including 30 outpatients with LC (Child-Pugh B\/C): 10 without diabetes (DM) (G1), 10 with newly diagnosed DM by oral glucose tolerance test (G2), and 10 with a previous DM diagnosis (G3). isCGM (FreeStyle Libre Pro) was used for 56 days (four sensors\/patient). Blood tests were performed at baseline and after 28 and 56 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      No differences were found in the baseline characteristics, except for higher age in G3. There were significant differences between G1, G2 and G3 in glucose management indicator (GMI) (5.28 \u00b1 0.17, 6.03 \u00b1 0.59, 6.86 \u00b1 1.08%,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .001), HbA1c (4.82 \u00b1 0.39, 5.34 \u00b1 1.26, 6.97 \u00b1 1.47%,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .001), average glucose (82.79 \u00b1 7.06, 113.39 \u00b1 24.32, 149.14 \u00b1 45.31mg\/dL,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .001), time in range (TIR) (70.89 \u00b1 9.76, 80.2 \u00b1 13.55, 57.96 \u00b1 17.96%,\n                      <jats:italic>P<\/jats:italic>\n                      = .006), and glucose variability (26.1 \u00b1 5.0, 28.21 \u00b1 5.39, 35.31 \u00b1 6.85%,\n                      <jats:italic>P<\/jats:italic>\n                      = .004). There was discordance between GMI and HbA1c when all groups were considered together, with a mean difference of 0.35% (95% SD 0.17, 0.63). In G1, the mean difference was 0.46% (95% SD 0.19, 0.73) and in G2 0.69% (95% SD 0.45, 1.33). GMI and HbA1c were concordant in G3, with a mean difference of \u22120.10 % (95% SD [\u22120.59, 0.38]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Disagreements were found between the GMI and HbA1c levels in patients with LC. isCGM was able to detect abnormalities in glycemic control that would not be detected by monitoring with HbA1c, suggesting that isCGM can be useful in assessing glycemic control in patients with LC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/19322968241232686","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T02:27:55Z","timestamp":1709605675000},"page":"1023-1034","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Intermittently Scanned Continuous Glucose Monitoring Performance in Patients With Liver Cirrhosis"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-0275","authenticated-orcid":false,"given":"Fernanda Augustini","family":"Rigon","sequence":"first","affiliation":[{"name":"Graduate Program in Medical Sciences, Polydoro Ernani de S\u00e3o Thiago University Hospital, Federal University of Santa Catarina, Florian\u00f3polis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Fernando","family":"Ronsoni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Federal University of Santa Catarina, Florian\u00f3polis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-5837","authenticated-orcid":false,"given":"Alexandre","family":"Hohl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Federal University of Santa Catarina, Florian\u00f3polis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Gustavo Daher","family":"Vianna","sequence":"additional","affiliation":[{"name":"Curitiba Diabetes Center, Department of Endocrine Diseases, Hospital Nossa Senhora das Gra\u00e7as, Curitiba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone van de","family":"Sande-Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Federal University of Santa Catarina, Florian\u00f3polis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo de Lucca","family":"Schiavon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Federal University of Santa Catarina, Florian\u00f3polis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Picardi A D\u2019Avola D Gentilucci UV et al. Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab Res Rev. 2006;22(4):274-283. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dmrr.636. Accessed August 16 2022.","DOI":"10.1002\/dmrr.636"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Kishimoto M Noda M. Verification of glycemic profiles using continuous glucose monitoring: cases with steroid use liver cirrhosis enteral nutrition or late dumping syndrome. J Med Invest. 2015;62(1-2):1-10. https:\/\/www.jstage.jst.go.jp\/article\/jmi\/62\/1.2\/62_1\/_article. Accessed August 16 2022.","DOI":"10.2152\/jmi.62.1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Kawaguchi T. Insulin resistance and chronic liver disease. World J Hepatol. 2011;3(5):99. http:\/\/www.wjgnet.com\/1948-5182\/full\/v3\/i5\/99.htm. Accessed August 16 2022.","DOI":"10.4254\/wjh.v3.i5.99"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Elkrief L Rautou PE Sarin S Valla D Paradis V Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36(7):936-948. http:\/\/doi.wiley.com\/10.1111\/liv.13115. Accessed February 22 2019.","DOI":"10.1111\/liv.13115"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31030-0"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Garcia-Compean D Jaquez-Quintana JO Gonzalez-Gonzalez JA Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors pathophysiology clinical implications and management. World J Gastroenterol. 2009;15(3):280. http:\/\/www.wjgnet.com\/1007-9327\/full\/v15\/i3\/280.htm. Accessed April 22 2021.","DOI":"10.3748\/wjg.15.280"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Liu TL Trogdon J Weinberger M Fried B Barritt AS4th. Diabetes is associated with clinical decompensation events in patients with cirrhosis. Dig Dis Sci. 2016;61(11):3335-3345. http:\/\/link.springer.com\/10.1007\/s10620-016-4261-8. Accessed August 16 2022.","DOI":"10.1007\/s10620-016-4261-8"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Silva TE Ronsoni MF Schiavon LL. Challenges in diagnosing and monitoring diabetes in patients with chronic liver diseases. Diabetes Metab Syndr. 2018;12(3):431-440. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402117304435. Accessed March 2 2019.","DOI":"10.1016\/j.dsx.2017.12.013"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Lenters-Westra E Schindhelm RK Bilo HJ Slingerland RJ. Haemoglobin A1c: historical overview and current concepts. Diabetes Res Clin Pract. 2013;99(2):75-84. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822712003749. Accessed July 10 2022.","DOI":"10.1016\/j.diabres.2012.10.007"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Nadelson J Satapathy SK Nair S. Glycated hemoglobin levels in patients with decompensated cirrhosis. Int J Endocrinol. 2016;2016:8390210. https:\/\/www.hindawi.com\/journals\/ije\/2016\/8390210\/. Accessed July 10 2022.","DOI":"10.1155\/2016\/8390210"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Koga M Kasayama S Kanehara H Bando Y. CLD (chronic liver diseases)-HbA1C as a suitable indicator for estimation of mean plasma glucose in patients with chronic liver diseases. Diabetes Res Clin Pract. 2008;81(2):258-262. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822708001940. Accessed February 16 2019.","DOI":"10.1016\/j.diabres.2008.04.012"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Wright LA Hirsch IB. Metrics beyond hemoglobin A1C in diabetes management: time in range hypoglycemia and other parameters. Diabetes Technol Ther. 2017;19(suppl 2):S16-S26. http:\/\/www.liebertpub.com\/doi\/10.1089\/dia.2017.0029. Accessed February 16 2019.","DOI":"10.1089\/dia.2017.0029"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Constanti C Simo JM Joven J Camps J. Serum fructosamine concentration in patients with nephrotic syndrome and with cirrhosis of the liver: the influence of hypoalbuminaemia and hypergammaglobulinaemia. Ann Clin Biochem. 1992;29(pt 4):437-442. https:\/\/journals.sagepub.com\/doi\/10.1177\/000456329202900412?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed. Accessed February 17 2019.","DOI":"10.1177\/000456329202900412"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/33.12.2153"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Koga M Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J. 2010;57(9):751-762. http:\/\/joi.jlc.jst.go.jp\/JST.JSTAGE\/endocrj\/K10E-138?from=CrossRef. Accessed February 16 2019.","DOI":"10.1507\/endocrj.K10E-138"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Dunn TC Xu Y Hayter G Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37-46. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882271731104X. Accessed August 16 2022.","DOI":"10.1016\/j.diabres.2017.12.015"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Heinemann L. Finger pricking and pain: a never ending story. J Diabetes Sci Technol. 2008;2(5):919-921. http:\/\/journals.sagepub.com\/doi\/10.1177\/193229680800200526. Accessed August 16 2022.","DOI":"10.1177\/193229680800200526"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Haak T Hanaire H Ajjan R Hermanns N Riveline JP Rayman G. Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther. 2017;8(3):573-586. http:\/\/link.springer.com\/10.1007\/s13300-017-0255-6. Accessed October 10 2019.","DOI":"10.1007\/s13300-017-0255-6"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Ish-Shalom M Wainstein J Raz I Mosenzon O. Improvement in glucose control in difficult-to-control patients with diabetes using a novel flash glucose monitoring device. J Diabetes Sci Technol. 2016;10(6):1412-1413. http:\/\/journals.sagepub.com\/doi\/10.1177\/1932296816653412. Accessed August 16 2022.","DOI":"10.1177\/1932296816653412"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Leelarathna L Wilmot EG. Flash forward: a review of flash glucose monitoring. Diabet Med. 2018;35(4):472-482. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.13584. Accessed August 16 2022.","DOI":"10.1111\/dme.13584"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Bailey T Bode BW Christiansen MP Klaff LJ Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17(11):787-794. http:\/\/www.liebertpub.com\/doi\/10.1089\/dia.2014.0378. Accessed February 23 2019.","DOI":"10.1089\/dia.2014.0378"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Al Hayek AA Robert AA Al Dawish MA. Differences of freestyle libre flash glucose monitoring system and finger pricks on clinical characteristics and glucose monitoring satisfactions in type 1 diabetes using insulin pump. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419861102. http:\/\/journals.sagepub.com\/doi\/10.1177\/1179551419861102. Accessed August 16 2022.","DOI":"10.1177\/1179551419861102"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee; ElSayed NA Aleppo G Bannuru RR et al. Diabetes technology: standards of care in diabetes\u20142024. Diabetes Care. 2024;47(suppl 1):S126-S144. https:\/\/diabetesjournals.org\/care\/article\/47\/Supplement_1\/S126\/153939\/7-Diabetes-Technology-Standards-of-Care-in. Accessed January 12 2024.","DOI":"10.2337\/dc24-S007"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Lu J Ying Z Wang P Fu M Han C Zhang M. Effects of continuous glucose monitoring on glycaemic control in type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(1):362-372. https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15328. Accessed January 17 2024.","DOI":"10.1111\/dom.15328"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Teo E Hassan N Tam W Koh S. Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. Diabetologia. 2022;65(4):604-619. https:\/\/link.springer.com\/10.1007\/s00125-021-05648-4. Accessed Jan 12 2024.","DOI":"10.1007\/s00125-021-05648-4"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Owen OE Trapp VE Reichard GAJr et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. J Clin Invest. 1983;72(5):1821-1832. http:\/\/www.jci.org\/articles\/view\/111142. Accessed February 17 2019.","DOI":"10.1172\/JCI111142"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Rigon FA Ronsoni MF Vianna AGD et al. Flash glucose monitoring system in special situations. Arch Endocrinol Metab. 2022;66(6):883-894. https:\/\/www.aem-sbem.com\/article\/flash-glucose-monitoring-system-in-special-situations\/. Accessed July 2 2022.","DOI":"10.20945\/2359-3997000000479"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142022. Abridged for primary care providers. Clin Diabetes. 2022;40(1):10-38. https:\/\/diabetesjournals.org\/clinical\/article\/40\/1\/10\/139035\/Standards-of-Medical-Care-in-Diabetes-2022. Accessed July 16 2022.","DOI":"10.2337\/cd22-as01"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Weissenborn K. Hepatic encephalopathy: definition clinical grading and diagnostic principles. Drugs. 2019;79(suppl 1):5-9. http:\/\/link.springer.com\/10.1007\/s40265-018-1018-z. Accessed July 24 2023.","DOI":"10.1007\/s40265-018-1018-z"},{"key":"e_1_3_2_31_2","volume-title":"Semiologia Nutricional","author":"Duarte AC","year":"2002","unstructured":"Duarte AC, Castellani FR. Semiologia Nutricional. Rio de janeiro: Axcel Books, 2002."},{"key":"e_1_3_2_32_2","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"Child CG","year":"1964","unstructured":"Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1-85.","journal-title":"Major Probl Clin Surg"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Kamath PS Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797-805. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hep.21563. Accessed July 12 2022.","DOI":"10.1002\/hep.21563"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Levy JC Matthews DR Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21(12):2191-2192. https:\/\/diabetesjournals.org\/care\/article\/21\/12\/2191\/21899\/Correct-Homeostasis-Model-Assessment-HOMA. Accessed July 24 2023.","DOI":"10.2337\/diacare.21.12.2191"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","unstructured":"Danne T Nimri R Battelino T et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631-1640. https:\/\/diabetesjournals.org\/care\/article\/40\/12\/1631\/37000\/International-Consensus-on-Use-of-Continuous. Accessed August 16 2022.","DOI":"10.2337\/dc17-1600"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","unstructured":"Bergenstal RM Beck RW Close KL et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275-2280. https:\/\/diabetesjournals.org\/care\/article\/41\/11\/2275\/36593\/Glucose-Management-Indicator-GMI-A-New-Term-for. Accessed July 11 2022.","DOI":"10.2337\/dc18-1581"},{"key":"e_1_3_2_37_2","unstructured":"Battelino T Danne T Bergenstal RM et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603. http:\/\/care.diabetesjournals.org\/lookup\/doi\/10.2337\/dci19-0028. Accessed November 20 2021."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/19322968221085273"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","unstructured":"Lin R Brown F Ekinci EI. The ambulatory glucose profile and its interpretation. Med J Aust. 2022;217(6):295-298. https:\/\/onlinelibrary.wiley.com\/doi\/10.5694\/mja2.51666. Accessed August 31 2022.","DOI":"10.5694\/mja2.51666"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","unstructured":"Dunn TC Xu Y Bergenstal RM Ogawa W Ajjan RA. Personalized glycated hemoglobin in diabetes management: closing the gap with glucose management indicator. Diabetes Technol Ther. 2023;25(suppl 3):S65-S74. https:\/\/www.liebertpub.com\/doi\/10.1089\/dia.2023.0146. Accessed January 12 2024.","DOI":"10.1089\/dia.2023.0146"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","unstructured":"Gomez-Peralta F Choudhary P Cosson E Irace C Rami-Merhar B Seibold A. Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin. Diabetes Obes Metab. 2022;24(4):599-608. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dom.14638. Accessed August 21 2022.","DOI":"10.1111\/dom.14638"},{"issue":"4","key":"e_1_3_2_42_2","first-page":"185","article-title":"Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease","volume":"7","author":"Cacciatore L","year":"1988","unstructured":"Cacciatore L, Cozzolino G, Giardina MG, et al. Abnormalities of glucose metabolism induced by liver cirrhosis and glycosylated hemoglobin levels in chronic liver disease. Diabetes Res. 1988;7(4):185-188.","journal-title":"Diabetes Res"},{"key":"e_1_3_2_43_2","first-page":"847","article-title":"Clinical significance of HbA1c, serum fructosamine and 1,5-AG in diabetic patients complicated with liver cirrhosis","volume":"36","author":"Kanda T","year":"1993","unstructured":"Kanda T, Nakamura M, Iwasaki M, Wada M, Kurotobi M, Shimizu Y. Clinical significance of HbA1c, serum fructosamine and 1,5-AG in diabetic patients complicated with liver cirrhosis. J Japan Diabetes Soc. 1993;36:847-854.","journal-title":"J Japan Diabetes Soc"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Kuenen JC Borg R Kuik DJ et al. Does glucose variability influence the relationship between mean plasma glucose and HbA 1c levels in type 1 and type 2 diabetic patients? Diabetes Care. 2011;34(8):1843-1847. http:\/\/care.diabetesjournals.org\/lookup\/doi\/10.2337\/dc10-2217. Accessed February 17 2019.","DOI":"10.2337\/dc10-2217"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","unstructured":"Liu H Yang D Deng H et al. Impacts of glycemic variability on the relationship between glucose management indicator from iPro\u21222 and laboratory hemoglobin A1c in adult patients with type 1 diabetes mellitus. Ther Adv Endocrinol Metab. 2020;11:2042018820931664. Published 2020 June 8. http:\/\/journals.sagepub.com\/doi\/10.1177\/2042018820931664. Accessed August 25 2022.","DOI":"10.1177\/2042018820931664"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","unstructured":"Barron CVM Heenan HF Thompson H Chan H Ngu J Lunt H. Detecting dysglycaemia in compensated liver cirrhosis: comparison of oral glucose tolerance test and glycated haemoglobin with continuous glucose monitoring. Diabet Med. 2022;3939(3):e14778. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.14778. Accessed August 26 2022.","DOI":"10.1111\/dme.14778"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","unstructured":"Addepally NS George N Martinez-Macias R Garcia-Saenz-de-Sicilia M Kim WR Duarte-Rojo A. Hemoglobin A1c has suboptimal performance to diagnose and monitor diabetes mellitus in patients with cirrhosis. Dig Dis Sci. 2018;63(12):3498-3508. http:\/\/link.springer.com\/10.1007\/s10620-018-5265-3. Accessed February 22 2019.","DOI":"10.1007\/s10620-018-5265-3"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","unstructured":"Honda F Hiramatsu A Hyogo H et al. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring. PLoS ONE. 2018;13(4):e0195028. https:\/\/dx.plos.org\/10.1371\/journal.pone.0195028. Accessed February 16 2019.","DOI":"10.1371\/journal.pone.0195028"},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","unstructured":"Ogawa Y Nakahara T Ono M et al. Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. J Gastroenterol Hepatol. 2022;37(3):592-599. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.15766. Accessed August 31 2022.","DOI":"10.1111\/jgh.15766"},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","unstructured":"Perlman JE Gooley TA McNulty B Meyers J Hirsch IB. HbA1c and glucose management indicator discordance: a real-world analysis. Diabetes Technol Ther. 2021;23(4):253-258. https:\/\/www.liebertpub.com\/doi\/10.1089\/dia.2020.0501. Accessed August 22 2022.","DOI":"10.1089\/dia.2020.0501"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","unstructured":"Oriot P Viry C Vandelaer A et al. Discordance between glycated hemoglobin A1c and the glucose management indicator in people with diabetes and chronic kidney disease. J Diabetes Sci Technol. 2022;17(6):1553\u20131562. http:\/\/journals.sagepub.com\/doi\/10.1177\/19322968221092050. Accessed August 22 2022.","DOI":"10.1177\/19322968221092050"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","unstructured":"Blum A. Freestyle libre glucose monitoring system. Clin Diabetes. 2018;36(2):203-204. https:\/\/diabetesjournals.org\/clinical\/article\/36\/2\/203\/32874\/Freestyle-Libre-Glucose-Monitoring-System. Accessed January 12 2024.","DOI":"10.2337\/cd17-0130"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","unstructured":"Costa D Louren\u00e7o J Monteiro AM et al. Clinical performance of flash glucose monitoring system in patients with liver cirrhosis and diabetes mellitus. Sci Rep. 2020;10(1):7460. http:\/\/www.nature.com\/articles\/s41598-020-64141-x. Accessed June 25 2022.","DOI":"10.1038\/s41598-020-64141-x"}],"container-title":["Journal of Diabetes Science and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19322968241232686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/19322968241232686","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19322968241232686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:16:52Z","timestamp":1777400212000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/19322968241232686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1177\/19322968241232686"],"URL":"https:\/\/doi.org\/10.1177\/19322968241232686","relation":{},"ISSN":["1932-2968","1932-2968"],"issn-type":[{"value":"1932-2968","type":"print"},{"value":"1932-2968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}